KD Logo

A Guide To The Risks Of Investing In Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc’s recently made public that its Director MCPEAK MERRILL A acquired Company’s shares for reported $2.29 million on Feb 20 ’24. In the deal valued at $9.15 per share,250,000 shares were bought. As a result of this transaction, MCPEAK MERRILL A now holds 320,150 shares worth roughly $2.99 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Dukes Iain D. bought 32,000 shares, generating $292,800 in total proceeds. Upon buying the shares at $9.15, the Director now owns 54,000 shares.

Before that, Rothbaum Wayne P. bought 5,000,000 shares. Iovance Biotherapeutics Inc shares valued at $45,750,000 were divested by the Director at a price of $9.15 per share. As a result of the transaction, Rothbaum Wayne P. now holds 28,067,333 shares, worth roughly $262.43 million.

Piper Sandler downgraded its Iovance Biotherapeutics Inc [IOVA] rating to a Neutral from a an Overweight in a research note published on July 29, 2024; the price target was decreased to $10 from $19. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid November with a ‘”a Buy”‘ rating. Barclays also remained covering IOVA and reiterated its “an Overweight” recommendation on September 18, 2023. Wells Fargo revised its rating on May 30, 2023. It rated IOVA as “an Overweight” which previously was an “an Equal weight”.

Price Performance Review of IOVA

On Tuesday, Iovance Biotherapeutics Inc [NASDAQ:IOVA] saw its stock fall -0.43% to $9.35. Over the last five days, the stock has gained 0.11%. Iovance Biotherapeutics Inc shares have risen nearly 15.01% since the year began. Nevertheless, the stocks have risen 105.49% over the past one year. While a 52-week high of $18.33 was reached on 02/28/24, a 52-week low of $3.21 was recorded on 08/05/24. SMA at 50 days reached $9.88, while 200 days put it at $10.44.

Levels Of Support And Resistance For IOVA Stock

The 24-hour chart illustrates a support level at 9.07, which if violated will result in even more drops to 8.80. On the upside, there is a resistance level at 9.52. A further resistance level may holdings at 9.70. The Relative Strength Index (RSI) on the 14-day chart is 43.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.61%. Stochastics %K at 26.01% indicates the stock is a holding.

How much short interest is there in Iovance Biotherapeutics Inc?

A steep rise in short interest was recorded in Iovance Biotherapeutics Inc stocks on 2024-09-13, growing by 0.96 million shares to a total of 60.29 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 59.33 million shares. There was a rise of 1.59%, which implies that there is a positive sentiment for the stock.

Most Popular